Back to Prevention

Does HIV Treatment Prevent Other Infections Too?

Does HIV Treatment Prevent Other Infections Too?
Bareback Guide 21 May 2026

Largely no. HIV treatment suppresses HIV and, incidentally, hepatitis B. It has no effect on gonorrhoea, chlamydia, syphilis, herpes, HPV, hepatitis A, hepatitis C or mpox, and someone assuming otherwise will miss infections that need finding.

Why does hepatitis B come along?

Because tenofovir and emtricitabine, common components of both HIV treatment and PrEP, are active against hepatitis B as well. Someone on a regimen containing them who also has chronic hepatitis B is suppressing both. This has a serious implication: stopping or switching to a regimen without those drugs can allow hepatitis B to rebound and cause a flare. This is why hepatitis B status is checked before treatment starts and why regimen changes are planned rather than improvised.

What about immune recovery?

Restoring immune function does reduce vulnerability to opportunistic infections such as pneumocystis pneumonia, cryptococcal disease and cytomegalovirus, which is a genuine and substantial benefit of treatment. It does not confer protection against ordinary sexually transmitted infections, which affect people with normal immune systems just as readily.

Does suppression reduce transmission of anything else?

No. An undetectable viral load describes HIV alone. Someone with a sustained undetectable viral load can transmit gonorrhoea, syphilis, mpox and everything else exactly as anyone can. This is a frequent misunderstanding and worth stating plainly, because it affects what partners assume.

Does having HIV change the risk of other infections?

In some ways yes. HPV persists more readily where immune function is reduced, and anal cancer rates are higher in people living with HIV, particularly those with a history of a low CD4 count. Syphilis can behave more aggressively and is more likely to affect the eyes or nervous system. Hepatitis C progresses faster with HIV co-infection. These are reasons for more attentive screening rather than less.

What should screening cover?

The same as for anyone else, at the same intervals: chlamydia and gonorrhoea from every site used, syphilis, and hepatitis B and C at least annually. Many HIV clinics build this into routine appointments, but not all do consistently, so it is worth asking what your last screen actually covered rather than assuming.

What about vaccination?

Hepatitis A, HPV, mpox and the meningococcal B vaccine where the gonorrhoea programme runs are all relevant and available. People living with HIV usually receive extra doses of some vaccines, and hepatitis B vaccination is offered to those not already infected or immune. Annual influenza and pneumococcal vaccination are also recommended.

Does anything else help?

Doxy-PEP reduces chlamydia and syphilis substantially where it is available, and people living with HIV were included in the trials and are eligible under most protocols. Condoms remain effective against the infections neither treatment nor doxycycline covers.

What about opportunistic infections?

These are the conditions that occur when immune function is significantly reduced, and effective treatment prevents them by restoring CD4 counts. Someone diagnosed with a very low count may be given preventive antibiotics for a period until recovery, which is a separate and temporary measure. Once suppressed with a recovered count, the risk returns to close to that of anyone else.

Does co-infection change treatment?

Sometimes. Hepatitis B influences which regimen is chosen, since some drugs cover both. Hepatitis C treatment can interact with certain antiretrovirals and needs coordinating between teams. Tuberculosis treatment has significant interactions and requires specialist management. Tell each service what the other is doing, because records do not join up automatically.

The practical position

Treatment does one enormous thing and one incidental one. Everything else on the list needs the same attention it would need for anyone, which means asking your clinic what your screening actually included and which vaccinations you are still due.

Does anything about treatment increase risk?

No. Antiretroviral treatment does not make you more susceptible to anything, and restoring immune function reduces vulnerability to several conditions. Where rates of bacterial infections are higher in people living with HIV, that reflects sexual networks and screening frequency rather than any effect of the drugs.

What should you ask at your next appointment?

Which sites your last screen covered, whether hepatitis C was included, which vaccinations you are still due, and whether anal screening is available locally. Four questions that close most of the gaps treatment leaves open.